on ABIVAX (EPA:ABVX)
Abivax: Terms of the Annual General Meeting and outlook for 2025
Biotechnology company Abivax announced that its Annual General Meeting will be held on June 6, 2025, in Paris. This announcement comes as the company advances key milestones, including its Phase 3 ABTECT program. The trials are expected to finalize patient enrollment in the second quarter of 2025, with results expected in the third quarter.
Marc de Garidel, CEO, highlighted the importance of 2025 for Abivax, marked by its investment in 120,000 shares. This decision aims to strengthen shareholder confidence as it approaches a potential commercialization. Abivax's lead candidate, obefazimod, targets chronic inflammatory diseases and is currently in phase 3 clinical trials.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news